Establishment of a human hepatoma multidrug resistant cell line in vitro

World Journal of Gastroenterology

Volumn 16, Issue 18, 2010, Pages 2291-2297

  Zhou, Yuan ^a   Ling, Xian Long ^a   Li, Shi Wei ^a   Li, Xin Qiang ^a   Yan, Bin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cell line; Cisplatin; Hepatoma; In vitro; Multidrug resistance

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; VINCRISTINE;

ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; CROSS RESISTANCE; GROWTH CURVE; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; PHENOTYPE; PROTEIN EXPRESSION;

EID: 77952656701     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i18.2291     Document Type: Article

References (13)

1. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006; 13: 1859-1876
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156
3. Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, Verslype C, Nevens F, Roskams T. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008; 28: 1370-1380
4. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002; 3: 593-603
5. Lasagna N, Fantappiè O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 2006; 66: 2673-2682
6. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12: 927-941
7. Twentyman PR, Fox NE, Wright KA, Bleehen NM. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer 1986; 53: 529-537
8. Iwasaki I, Sugiyama H, Kanazawa S, Hemmi H. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles. Cancer Chemother Pharmacol 2002; 49: 438-444
9. Watson MB, Lind MJ, Cawkwell L. Establishment of in-vitro models of chemotherapy resistance. Anticancer Drugs 2007; 18: 749-754
10. Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, Park YN. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004; 40: 298-304
11. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-416
12. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 2005; 25: 367-379
13. Nies AT, König J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 2001; 94: 492-499